JaLCDOI 10.18926/AMO/56868
フルテキストURL 73_3_247.pdf
著者 Yoshio, Kotaro| Wakita, Akihisa| Mitsuhashi, Toshiharu| Kitayama, Takahiro| Hisazumi, Kento| Inoue, Daisaku| Tajiri, Nobuhisa| Shiode, Tsuyoki| Akaki, Shiro| Kanazawa, Susumu|
抄録 We investigated the feasibility of simultaneous integrated boost (SIB) volumetric modulated arc therapy (VMAT) using elective nodal irradiation (ENI) for middle or lower esophageal cancer and compared it with three-dimensional conformal radiotherapy (3D-CRT). The study included 15 patients. The prescribed doses included a standard dose (50.4 Gy) and a high dose (60 Gy) for the planning target volume (PTV) of the involved lesions. The objective of the whole lung volume receiving ≥ 20 Gy (V20Gy) was < 30%, and the mean lung dose (MLD) was < 20 Gy. The volumes of the lung receiving 5 Gy (V5Gy) and the heart receiving 30-50 Gy (V30-50Gy) were kept as low as reasonably achievable. As a result, SIB-VMAT showed superior dose conformity for the PTV (p<0.001). Although the lung V5Gy was significantly increased (p<0.001), the V20Gy and MLD showed no significant increase. The heart V30-50Gy showed a > 20% reduction in the mean against 3D-CRTs. Our results demonstrate the feasibility of SIB-VMAT for the treatment of middle or lower esophageal cancer with ENI. Although attention should be paid to the low-dose area of the lungs, SIB-VMAT would be a promising treatment option with improved outcomes for esophageal cancer.
キーワード esophageal cancer middle and lower thoracic volumetric modulated arc therapy, 3D-CRT elective nodal irradiation
Amo Type Original Article
発行日 2019-06
出版物タイトル Acta Medica Okayama
73巻
3号
出版者 Okayama University Medical School
開始ページ 247
終了ページ 257
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2019 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 31235973
JaLCDOI 10.18926/AMO/32906
フルテキストURL fulltext.pdf
著者 Mukai, Takashi| Mimura, Hidefumi| Gobara, Hideo| Takemoto, Mitsuhiro| Himei, Kengo| Hiraki, Takao| Hase, Soichiro| Fujiwara, Hiroyasu| Iguchi, Toshihiro| Tajiri, Nobuhisa| Sakurai, Jun| Yasui, Kotaro| Sano, Yoshifumi| Date, Hiroshi| Kanazawa, Susumu|
抄録 We report the clinical experience of radiofrequency ablation followed by radiation therapy for large primary lung tumors. Two patients with large primary lung tumors were treated with combined radiofrequency ablation and radiation therapy, and good local control was observed. Combined radiofrequency ablation and radiation therapy that involves minimally invasive techniques appears to be promising for the treatment of large lung tumors.
キーワード radiofrequency ablation lung cancer radiation therapy
Amo Type Case Report
発行日 2007-06
出版物タイトル Acta Medica Okayama
61巻
3号
出版者 Okayama University Medical School
開始ページ 177
終了ページ 180
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 17593954
Web of Sience KeyUT 000247574700008
JaLCDOI 10.18926/AMO/47010
フルテキストURL 65_5_287.pdf
著者 Hiraki, Takao| Gobara, Hideo| Mimura, Hidefumi| Toyooka, Shinichi| Fujiwara, Hiroyasu| Yasui, Kotaro| Sano, Yoshifumi| Iguchi, Toshihiro| Sakurai, Jun| Tajiri, Nobuhisa| Mukai, Takashi| Matsui, Yusuke| Kanazawa, Susumu|
抄録 The application of radiofrequency ablation for the treatment of lung cancer by our group at Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences began in June 2001, and in the present report, we review our 10-year experience with this treatment modality at Okayama University Hospital. The local efficacy of radiofrequency ablation for the treatment of lung cancer depends on tumor size and the type of electrode used, but not on tumor type. An important factor for the prevention of local failure may be the acquisition of an adequate ablative margin. The combination of embolization and radiation therapy enhances the local efficacy. Local failure may be salvaged by repeating the radiofrequency ablation, particularly in small tumors. Survival rates after radiofrequency ablation are quite promising for patients with clinical stage I non-small cell lung cancer and pulmonary metastasis from colorectal cancer, hepatocellular carcinoma, and renal cell carcinoma. The complications caused by radiofrequency ablation can be treated conservatively in the majority of cases. However, attention should be paid to rare but serious complications. This review shows that radiofrequency ablation is a promising treatment for patients with lung cancer.
キーワード radiofrequency ablation lung cancer local efficacy survival complication
Amo Type Review
発行日 2011-10
出版物タイトル Acta Medica Okayama
65巻
5号
出版者 Okayama University Medical School
開始ページ 287
終了ページ 297
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2011 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 22037265
Web of Sience KeyUT 000296116400002